Valeant Pharmaceuticals International Inc. (VRX)

22.85
0.81 3.42
NYSE : Health Technology
Prev Close 23.66
Open 23.50
Day Low/High 22.27 / 23.62
52 Wk Low/High 14.44 / 28.45
Volume 4.32M
Avg Volume 7.97M
Exchange NYSE
Shares Outstanding 348.84M
Market Cap 8.04B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Trouble With Trump's Tariffs: Cramer's 'Mad Money' Recap (Friday 6/22/18)

The Trouble With Trump's Tariffs: Cramer's 'Mad Money' Recap (Friday 6/22/18)

Trump's doubling down on trade issues. If you can't stand the pressure, then raise cash. Jim Cramer has your game plan for next week.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Valeant Pharmaceuticals International, Inc. - VRX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Valeant Pharmaceuticals International, Inc. - VRX

NEW YORK, June 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Valeant Pharmaceuticals International, Inc.

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Valeant Pharmaceuticals International, Inc. (VRX)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Valeant Pharmaceuticals International, Inc. (VRX)

NEW YORK, June 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Valeant Pharmaceuticals International, Inc.

FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate And Tazarotene) Lotion

FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate And Tazarotene) Lotion

LAVAL, Quebec, June 18, 2018 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc.

Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't

Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't

You should be thinking positively these days if your stock has had a run or even if it hasn't as a preponderance of good things is liable to happen.

Securities Class Action Filed On Behalf Of Persons Or Entities That Traded Certain Derivative Securities Of Valeant Pharmaceuticals International, Inc. During The Period January 4, 2013 Through August 11, 2016, Inclusive

Securities Class Action Filed On Behalf Of Persons Or Entities That Traded Certain Derivative Securities Of Valeant Pharmaceuticals International, Inc. During The Period January 4, 2013 Through August 11, 2016, Inclusive

Entwistle & Cappucci LLP ("Entwistle & Cappucci") today announced that it has filed a securities class action lawsuit on behalf of persons or entities that purchased call options and/or sold put options on Valeant Pharmaceuticals International, Inc.

Replay: Jim Cramer on Bank Stocks, Cruise Stocks and Valeant Pharmaceuticals

Replay: Jim Cramer on Bank Stocks, Cruise Stocks and Valeant Pharmaceuticals

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending market topics from the floor of the New York Stock Exchange.

Jim Cramer: Barclays' $29 Price Target on Valeant Is 'Very Right'

Jim Cramer: Barclays' $29 Price Target on Valeant Is 'Very Right'

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer thinks Barclay's $29 price target on Valeant Pharmaceuticals is "very right."

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMGN, CIG.C, COTV, CTRE, GMS, HPT, IAG, NFEC, QGEN, SCVL, THR, TPHS, USFD, UVV Downgrades: BKE, IGT, TSLX, VRX Initiations: MGEN Read on to get TheStreet Quant Ratings' detailed report:

Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round

Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round

Jim Cramer weighs in on Royal Caribbean, Allergan, Tyson Foods, Carrizo Oil & Gas, Valeant Pharmaceuticals, Okta, CRISPR Therapeutics and more.

Ceasefire in Trade War: Cramer's 'Mad Money' Recap (Monday 5/21/18)

Ceasefire in Trade War: Cramer's 'Mad Money' Recap (Monday 5/21/18)

Jim Cramer says the hope that the trade dispute with China can be worked out was the fuel for this rally.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

All three major averages closed Thursday's session in positive territory.

Jim Cramer on Bausch Health: This Stock Is a Buy

Jim Cramer on Bausch Health: This Stock Is a Buy

Valeant Pharmaceuticals is changing its name to Bausch Health and the stock is a buy, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.

Video: Jim Cramer on Oil, Occidental Petroleum, Bausch Health and Etsy

Video: Jim Cramer on Oil, Occidental Petroleum, Bausch Health and Etsy

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.

Emotions Are Running This Market: Cramer's 'Mad Money' Recap (Tuesday 5/8/18)

Emotions Are Running This Market: Cramer's 'Mad Money' Recap (Tuesday 5/8/18)

Jim Cramer says the reason this market is so hard to deal with is that it doesn't know how to calculate an event -- even when everyone saw it coming.

Dow Trims Earlier Losses, Finishes Slightly Higher After Volatile Session

Dow Trims Earlier Losses, Finishes Slightly Higher After Volatile Session

Stocks finished mixed on Tuesday after President Trump announced that the U.S. would withdraw from the Iran nuclear deal.

Video: Jim Cramer on the Iran Deal Decision, Hain Celestial & Caterpillar

Video: Jim Cramer on the Iran Deal Decision, Hain Celestial & Caterpillar

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Tuesday's trending stocks from the floor of the New York Stock Exchange.

Can a Bold Name Change Help Valeant Escape Its Tarnished Reputation?

Can a Bold Name Change Help Valeant Escape Its Tarnished Reputation?

Valeant will become Bausch Health Cos. this summer. Here's what that could mean for the company as it continues to recover from controversy.

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

Jim Cramer takes a look at CVS Health, Prestige Brands, LendingTree, Valeant Pharmaceuticals, Nektar Therapeutics, Kirkland Lake and more.

Buffett's Optimism Rules: Cramer's 'Mad Money' Recap (Monday 5/7/18)

Buffett's Optimism Rules: Cramer's 'Mad Money' Recap (Monday 5/7/18)

Jim Cramer says Warren Buffett is the greatest investor, and his optimism has suffused trading and has been justified.

Short Seller Andrew Left Says Square Is a 'Collection of Yawn Businesses'

Short Seller Andrew Left Says Square Is a 'Collection of Yawn Businesses'

Wall Street is 'drunk on bitcoin nonsense,' Left says. He tells TheStreet why his Citron Research is taking an unpopular stance on Square.

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Masco's 4% drop Thursday is the latest proof that big call buying doesn't mean insiders know something you don't.

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

American Airlines, ABB Ltd., Salesforce.com: 'Mad Money' Lightning Round

American Airlines, ABB Ltd., Salesforce.com: 'Mad Money' Lightning Round

Jim Cramer focuses on American Airlines, Salesforce.com, Realty Income, Proctor & Gamble, United Bankshares, iRobot, Dominion Energy.

Rally Climbs on Earnings: Cramer's 'Mad Money' Recap (Thursday 4/12/18)

Rally Climbs on Earnings: Cramer's 'Mad Money' Recap (Thursday 4/12/18)

Good earnings reports, cooling oil, and tech leadership all contributed to Thursday's gains, says Jim Cramer. Along with no explosive presidential tweets.

Ready for Tesla's New Model Y? Here's When to Expect It

Ready for Tesla's New Model Y? Here's When to Expect It

Tesla's Model Y could begin production in November 2019, but don't get your hopes up.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.